Free Trial

Beta Bionics (BBNX) 10K Form and Latest SEC Filings 2026

Beta Bionics logo
$9.65 -0.20 (-2.04%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Beta Bionics SEC Filings & Recent Activity

Beta Bionics (NASDAQ:BBNX) has submitted 152+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G/A submitted on May 12, 2026.

Form 4
Beta Bionics, Inc. Reports Ownership Change on Mar. 16, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Beta Bionics Files Current Report on Apr. 21, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Beta Bionics Files Quarterly Report on Apr. 21, 2026

The 10-Q contains Beta Bionics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Beta Bionics SEC Filing History

Browse Beta Bionics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/12/2026 7:50 AM
Beta Bionics (1674632) Subject
Farallon Capital Partners, L.P. (1175707) Filed by
Form SCHEDULE 13G/A
05/08/2026 4:00 PM
Beta Bionics (1674632) Subject
Soleus Capital Group, LLC (1812276) Filed by
Form SCHEDULE 13G/A
04/21/2026 3:20 PM
Beta Bionics (1674632) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/21/2026 3:05 PM
Beta Bionics (1674632) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2026 3:25 PM
Beta Bionics (1674632) Filer
Form ARS
04/10/2026 3:15 PM
Beta Bionics (1674632) Filer
Form DEFA14A
03/26/2026 3:08 PM
Beta Bionics (1674632) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/16/2026 6:55 PM
Beta Bionics (1674632) Issuer
Russell Steven Jon (2051384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 6:55 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 3:15 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4/A
03/13/2026 3:15 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4/A
03/13/2026 3:15 PM
Beta Bionics (1674632) Issuer
Saint Sean (2048593) Reporting
Form 4/A
03/13/2026 3:15 PM
Beta Bionics (1674632) Issuer
Russell Steven Jon (2051384) Reporting
Form 4/A
03/13/2026 3:15 PM
Beta Bionics (1674632) Issuer
Mensinger Mike (2048500) Reporting
Form 4/A
03/05/2026 6:30 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 5:02 PM
Beta Bionics (1674632) Subject
Hopman Mark (2048497) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2026 3:58 PM
Beta Bionics (1674632) Subject
Mensinger Mike (2048500) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2026 3:54 PM
Beta Bionics (1674632) Subject
Saint Sean (2048593) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2026 3:56 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2026 5:45 PM
Beta Bionics (1674632) Issuer
Saint Sean (2048593) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:45 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:45 PM
Beta Bionics (1674632) Issuer
Mensinger Mike (2048500) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:45 PM
Beta Bionics (1674632) Issuer
Russell Steven Jon (2051384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:45 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2026 5:09 PM
Beta Bionics (1674632) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
02/17/2026 7:29 AM
Beta Bionics (1674632) Subject
RTW INVESTMENTS, LP (1493215) Filed by
Form SCHEDULE 13G/A
02/10/2026 10:23 AM
Beta Bionics (1674632) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
02/10/2026 10:27 AM
Beta Bionics (1674632) Subject
Wellington Hadley Harbor Aggregator IV, L.P. (2053997) Filed by
Form SCHEDULE 13G/A
02/09/2026 7:51 AM
Beta Bionics (1674632) Subject
Farallon Capital Partners, L.P. (1175707) Filed by
Form SCHEDULE 13G/A
01/30/2026 3:30 PM
Beta Bionics (1674632) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/14/2026 7:30 PM
Beta Bionics (1674632) Issuer
Dearen Danny L. (1756438) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:30 PM
Beta Bionics (1674632) Issuer
Lezack Adam (2048466) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:30 PM
Beta Bionics (1674632) Issuer
Jones Christy (2048467) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:30 PM
Beta Bionics (1674632) Issuer
Palasis Maria (1810701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:30 PM
Beta Bionics (1674632) Issuer
CARNEY SEAN (1239312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:30 PM
Beta Bionics (1674632) Issuer
MICHEL GERARD J (1235644) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:08 PM
Beta Bionics (1674632) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 3:16 PM
Beta Bionics (1674632) Issuer
Mensinger Mike (2048500) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 5:03 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 5:05 PM
Beta Bionics (1674632) Issuer
Mensinger Mike (2048500) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 3:27 PM
Beta Bionics (1674632) Subject
Mensinger Mike (2048500) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2026 3:29 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144/A
01/02/2026 3:17 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/04/2025 3:41 PM
Beta Bionics (1674632) Subject
Hopman Mark (2048497) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2025 3:20 PM
Beta Bionics (1674632) Issuer
Palasis Maria (1810701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 3:20 PM
Beta Bionics (1674632) Issuer
Lezack Adam (2048466) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 11:19 AM
Beta Bionics (1674632) Subject
Zone Healthcare Holdings, LLC (1814952) Filed by
Form SCHEDULE 13G/A
11/07/2025 11:01 AM
Beta Bionics (1674632) Subject
MORGAN STANLEY (895421) Filed by
Form SCHEDULE 13G/A
11/05/2025 8:45 PM
Beta Bionics (1674632) Issuer
Palasis Maria (1810701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2025 8:45 PM
Beta Bionics (1674632) Issuer
Lezack Adam (2048466) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 3:13 PM
Beta Bionics (1674632) Subject
Palasis Maria (1810701) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/31/2025 3:14 PM
Beta Bionics (1674632) Subject
Lezack Adam (2048466) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/30/2025 1:25 PM
Beta Bionics (1674632) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G
10/28/2025 3:20 PM
Beta Bionics (1674632) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/28/2025 3:04 PM
Beta Bionics (1674632) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 5:05 PM
Beta Bionics (1674632) Subject
BlackRock, Inc. (2012383) Filed by
Form SCHEDULE 13G
10/16/2025 3:03 PM
Beta Bionics (1674632) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
10/07/2025 3:15 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 2:34 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/01/2025 3:42 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/19/2025 3:21 PM
Beta Bionics (1674632) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G
09/09/2025 3:12 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2025 5:15 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2025 5:15 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2025 4:12 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2025 4:24 PM
Beta Bionics (1674632) Subject
Hopman Mark (2048497) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/04/2025 5:45 PM
Beta Bionics (1674632) Issuer
Saint Sean (2048593) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 5:45 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 5:45 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 5:45 PM
Beta Bionics (1674632) Issuer
Mensinger Mike (2048500) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 5:45 PM
Beta Bionics (1674632) Issuer
Russell Steven Jon (2051384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 10:10 AM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/20/2025 8:30 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 8:30 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 4:30 PM
Beta Bionics (1674632) Subject
Hopman Mark (2048497) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2025 4:41 PM
Beta Bionics (1674632) Subject
Feider Stephen (2048588) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2025 10:20 AM
Beta Bionics (1674632) Subject
Sands Capital Life Sciences Pulse Fund II, L.P. (1875620) Filed by
Form SCHEDULE 13G/A
08/07/2025 10:36 AM
Beta Bionics (1674632) Subject
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Form SCHEDULE 13G/A
07/29/2025 3:20 PM
Beta Bionics (1674632) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/23/2025 6:31 AM
Beta Bionics (1674632) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/09/2025 7:30 PM
Beta Bionics (1674632) Subject
Saint Sean (2048593) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/04/2025 6:30 PM
Beta Bionics (1674632) Issuer
Saint Sean (2048593) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 6:30 PM
Beta Bionics (1674632) Issuer
Feider Stephen (2048588) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 6:30 PM
Beta Bionics (1674632) Issuer
Mensinger Mike (2048500) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 6:30 PM
Beta Bionics (1674632) Issuer
Russell Steven Jon (2051384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 6:30 PM
Beta Bionics (1674632) Issuer
Hopman Mark (2048497) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2025 7:15 AM
Beta Bionics (1674632) Subject
RTW INVESTMENTS, LP (1493215) Filed by
Form SCHEDULE 13G
05/12/2025 9:50 AM
Beta Bionics (1674632) Subject
Wellington Hadley Harbor Aggregator IV, L.P. (2053997) Filed by
Form SCHEDULE 13G/A
05/12/2025 9:44 AM
Beta Bionics (1674632) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G
(Data available from 1/1/2016 forward)

Beta Bionics SEC Filings - Frequently Asked Questions

Beta Bionics (BBNX) has submitted 152+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Beta Bionics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 12, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BBNX) was last updated on 5/12/2026 by MarketBeat.com Staff.
From Our Partners